Trials / Unknown
UnknownNCT05102292
The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation
An Open Label, Multicenter Phase Ib/II Clinical Study to Evaluate Efficacy , Safety and PK of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Shanghai Henlius Biotech · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to assess efficacy, safety and PK in anaplastic thyroid cancer (ATC) given HLX208 (BRAF V600E inhibitor).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HLX208 | HLX208 450mg bid po |
Timeline
- Start date
- 2021-12-10
- Primary completion
- 2024-06-30
- Completion
- 2024-12-30
- First posted
- 2021-11-01
- Last updated
- 2023-08-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05102292. Inclusion in this directory is not an endorsement.